Jan 29 |
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
|
Jan 29 |
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
|
Jan 18 |
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
|
Jan 16 |
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
|
Dec 22 |
HOOKIPA Pharma files to sell 15M shares for holders
|
Dec 21 |
Hookipa Pharma stock soars on $21.25M equity investment from Gilead
|
Dec 21 |
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
|
Nov 20 |
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
|
Nov 9 |
HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023
|
Nov 9 |
HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M
|